DOI QR코드

DOI QR Code

Salvage Chemotherapy with Weekly Paclitaxel for Metastatic Melanoma

  • Ozaslan, Ersin (Department of Medical Oncology, Erciyes University Faculty of Medicine) ;
  • Aksoy, Asude (Department of Medical Oncology, Inonu University Faculty of Medicine) ;
  • Gumusay, Ozge (Department of Medical Oncology, Gazi University Faculty of Medicine) ;
  • Arpaci, Erkan (Department of Medical Oncology, Sakarya University Faculty of Medicine) ;
  • Berk, Veli (Department of Medical Oncology, Erciyes University Faculty of Medicine)
  • 발행 : 2015.04.03

초록

키워드

참고문헌

  1. Grimaldi AM, Cassidy PB, Leachmann S, Ascierto PA (2014). Novel approaches in melanoma prevention and therapy. Cancer Treat Res, 159, 443-55. https://doi.org/10.1007/978-3-642-38007-5_25
  2. Mamalis A, Garcha M, Jagdeo J (2014). Targeting the PD-1 pathway: a promising future for the treatment of melanoma. Arch Dermatol Res, 306, 511-9. https://doi.org/10.1007/s00403-014-1457-7
  3. Patel PM, Suciu S, Mortier L, et al (2011). EORTC Melanoma Group. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). Eur J Cancer, 47, 1476-83. https://doi.org/10.1016/j.ejca.2011.04.030
  4. Walker L, Schalch H, King DM, et al (2005). Phase II trial of weekly paclitaxel in patients with advanced melanoma. Melanoma Res, 15, 453-9. https://doi.org/10.1097/00008390-200510000-00015
  5. Zimpfer-Rechner C, Hofmann U, Figl R et al (2003). Randomized phase II study of weekly paclitaxel versus paclitaxel and carboplatin as second-line therapy in disseminated melanoma: a multicentre trial of the dermatologic co-operative oncology group (DeCOG). Melanoma Res, 13, 531-6. https://doi.org/10.1097/00008390-200310000-00012